Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Net Income: 2020-2025

Historic Net Income for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -$11.0 million.

  • Insight Molecular Diagnostics' Net Income rose 18.25% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.3 million, marking a year-over-year decrease of 41.10%. This contributed to the annual value of -$61.0 million for FY2024, which is 1986.16% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Net Income of -$11.0 million as of Q3 2025, which was down 12.25% from -$9.8 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' Net Income's 5-year high stood at -$2.9 million during Q1 2023, with a 5-year trough of -$35.7 million in Q4 2021.
  • Its 3-year average for Net Income is -$11.1 million, with a median of -$9.1 million in 2024.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Net Income crashed by 438.57% in 2021, and later surged by 71.57% in 2023.
  • Over the past 5 years, Insight Molecular Diagnostics' Net Income (Quarterly) stood at -$35.7 million in 2021, then climbed by 7.65% to -$33.0 million in 2022, then surged by 50.91% to -$16.2 million in 2023, then slumped by 107.84% to -$33.6 million in 2024, then increased by 18.25% to -$11.0 million in 2025.
  • Its last three reported values are -$11.0 million in Q3 2025, -$9.8 million for Q2 2025, and -$6.8 million during Q1 2025.